Acadia Pharmaceuticals Inc [ACAD] stock prices are up 2.33% to $25.43 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ACAD shares have gain 6.40% over the last week, with a monthly amount glided 12.03%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on October 21, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $33. Previously, Deutsche Bank upgraded its rating to Buy on May 21, 2025, and kept the price target unchanged to $35. On February 11, 2025, Deutsche Bank initiated with a Hold rating and assigned a price target of $22 on the stock. Guggenheim downgraded its rating to a Neutral and decreased its price target to $20 on January 03, 2025. Morgan Stanley downgraded its rating to Equal-Weight for this stock on August 07, 2024, and downed its price target to $20. In a note dated June 27, 2024, BMO Capital Markets initiated an Outperform rating and provided a target price of $31 on this stock.
The stock price of Acadia Pharmaceuticals Inc [ACAD] has been fluctuating between $13.40 and $26.65 over the past year. Currently, Wall Street analysts expect the stock to reach $29.75 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $25.43 at the most recent close of the market. An investor can expect a potential return of 16.99% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
The Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 1.05B for trailing twelve months, representing a surge of 11.27%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.23%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.22%. To continue investigating profitability, this company’s Return on Assets is posted at 0.18, Equity is 0.31 and Total Capital is 0.26. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.98 points at the first support level, and at 24.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.78, and for the 2nd resistance point, it is at 26.13.
Ratios To Look Out For
It’s worth pointing out that Acadia Pharmaceuticals Inc [NASDAQ:ACAD]’s Current Ratio is 3.02. Also, the Quick Ratio is 2.94, while the Cash Ratio stands at 0.77. Considering the valuation of this stock, the price to sales ratio is 4.11, the price to book ratio is 4.69 and price to earnings (TTM) ratio is 16.36.
Transactions by insiders
Recent insider trading involved Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, that happened on Nov 18 ’25 when 10262.0 shares were sold. PRINCIPAL ACCOUNTING OFFICER, Kihara James completed a deal on Nov 18 ’25 to sell 4084.0 shares. Meanwhile, Director Daly James M sold 30000.0 shares on Nov 10 ’25.
